Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

Healthcare costs and spending have been rising […] Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock ...

Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The headline numbers were ahead of estimates, while the pipeline details ...

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

Monitor your stock picks and compare them to top Wall ... Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on CRSP: CRISPR Therapeutics NewsMORE Related Stocks Indices Commodities ...

The stock option granted on November 5, 2024 has a ten-year term and an exercise price of $3.59 per share, which is equal to ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. Another industry also offers innovation and ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics CRSP is expected to report ... whether it would be a prudent move to buy, sell, or hold the stock at present. In the past year, thestock has plunged 41% compared with the ...